Pfizer PFE

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Bull Market: More to Run

      Headlines

      Mon, 2 Mar 2015

      A activity came when pharma giant Pfizer ( PFE ) announced the acquisition of Hospira ..... over the prior-day closing price. Pfizer would pay the 40% premium on top ..... objectives is tough to do. Essentially, Pfizer management believes the market has

    2. UPDATE 1- Pfizer , Novartis say meningitis vaccine scope too narrow

      Headlines

      Thu, 26 Feb 2015

      Feb 26 (Reuters) - A U.S. Centers for Disease Control and Prevention (CDC) advisory committee on Thursday recommended meningitis B vaccines for people at high risk aged 10 to 25, a population that...

    3. Pfizer laments narrow recommendation for meningitis vaccine

      Headlines

      Thu, 26 Feb 2015

      Feb 26 (Reuters) - An advisory committee to the U.S. Centers for Disease Control and Prevention (CDC) has recommended that people aged 10 to 25 at increased risk of meningitis be vaccinated against the bacteria, Pfizer Inc said on Thursday.

    4. UPDATE 1-Sanofi's new boss could earn more than Total's, less than Pfizer's

      Headlines

      Fri, 20 Feb 2015

      PARIS, Feb 20 (Reuters) - Sanofi's new boss Olivier Brandicourt could earn up to 4.2 million euros ($4.8 million) a year at the drugs group and pocket an extra 4 million euros within 12 months as a one-off golden handshake.

    5. Sanofi's Appointment of Brandicourt Replaces a Key Uncertainty With a Strong Leader

      Commentary

      Thu, 19 Feb 2015

      expected to enter the market in 2015. Also, Brandicourt brings a strong understanding of pricing pressure as the leader of Pfizer 's primary care business from 2009 to 2012, a time of major pricing pressure for cholesterol drug Lipitor and several

    6. Incyte Reports Another Solid Quarter of Jakafi Growth and Pipeline Progress

      Commentary

      Fri, 13 Feb 2015

      significant potential catalyst for the firm, we believe it faces a challenging environment given the disappointing launch of Pfizer 's Xeljanz. In addition, the broad Phase II program for IDO1 inhibitor INCB24360 continues to progress in combination

    7. Hospira Adjusts to Generic Precedex Challenge

      Commentary

      Thu, 12 Feb 2015

      on our earnings and cash flow projections for 2015, and we're leaving our $90 fair value estimate in place based on Pfizer 's recent announcement that it will purchase the company. We continue to believe Hospira's biosimilars pipeline, the

    8. Pfizer in $5 billion accelerated buyback deal with Goldman, Sachs & Co

      Headlines

      Mon, 9 Feb 2015

      (Reuters) - Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock.

    9. Pfizer in $5 bln accelerated buyback deal with Goldman, Sachs & Co

      Headlines

      Mon, 9 Feb 2015

      Feb 9 (Reuters) - Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock.

    10. Friday Five: What Will the Fed Do Now?

      Video Reports

      Fri, 6 Feb 2015

      that signal as well. Stipp: In stock news, [TICKER: PFE ] Pfizer ( PFE ) announced that it's paying a pretty decent premium ..... our take on that deal? Glaser: Damien Conover, our Pfizer analyst, thinks that it's going to be a good one for

      Pfizer PFE found at 3:25

      ECB was trying to send that signal as well. Stipp: In stock PFE Pfizer ( PFE ) announced that it's paying a pretty decent premium to acquire [TICKER:HSP] Hospira (HSP). What's our take on that deal? Glaser: Damien Conover, our Pfizer analyst, thinks that it's going to be a good one for the pharmaceutical giant. They're spending $16 billion for the maker of these injectable drugs, and he thinks that this will really widen Pfizer's already wide moat--that it will give them a way to really continue to leverage their salesforce, there global reach, with even more
    « Prev12345Next »
    Content Partners